Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | LPO | P22079 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 4/20 | 0.32 |
| ▸ | CDK8 | P49336 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20151886 | 0.82 | KDM4E (0.59) | KDM4EPFKFB3MAPTALDH1A1LMNA | |
| SCHEMBL950298 | 0.76 | KDM4E (0.65) | KDM4EMAPTALDH1A1LMNAGAA | |
| SCHEMBL30824582 | 0.76 | KDM4E (0.65) | KDM4EMAPTALDH1A1LMNAGAA | |
| SCHEMBL632748 | 0.73 | KDM4E (0.45) | KDM4EMAPTALDH1A1LMNAGAA | |
| SCHEMBL1396167 | 0.73 | KDM4E (0.45) | KDM4EMAPTALDH1A1LMNAGAA | |
| SCHEMBL21282869 | 0.72 | PFKFB3 (0.34) | KDM4EPFKFB3L3MBTL1 | |
| SCHEMBL14737917 | 0.70 | — | — | |
| SCHEMBL28802900 | 0.70 | — | — | |
| SCHEMBL2303823 | 0.70 | — | — | |
| SCHEMBL30824570 | 0.70 | KDM4E (0.42) | KDM4EMAPTALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256499-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INHIBITORS OF PFKFB | MERCK PATENT GMBH (DE) | 2019-08-22 | — | — | US | disclosed |
| WO-2018087021-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INHIBITORS OF PFKFB | MERCK PATENT GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256499-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INHIBITORS OF PFKFB | PFKFB1, PFKFB2, PFKFB4 | KDM4E 1601/4885PFKFB3 4/4885MAPT 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.